|Description||AZD2461 is a novel and potent PARP inhibitor with lower affinity to P-glycoprotein. AZD2641 is currently in Phase I clinical study. The study is being conducted to see how it may work to treat solid tumors. The study will also assess the blood levels and action of AZD2461 in the body over a period of time and will indicate whether the drug has a therapeutic effect on solid tumors.|
|Appearance||white solid powder|
|Synonyms||AZD2461; AZD 2461.|
MK-4827 tosylate is a selective inhibitor of PARP1/PARP2 with IC50 of 3.8 nM/2.1 nM. It has a great activity in cancer cells with mutant BRCA-1 and BRCA-2, >330...
Rucaparib, also named as AG-014699 or PF-01367338, is a poly (ADP ribose) polymerase (PARP) inhibitor. PARP is a DNA damage-activated nuclear enzyme that has a ...
Parstatin is a 41-amino acid peptide, formed by proteolytic cleavage on activation of the protease activated receptor-1, with antiangiogenic properties. Parstat...
PJ34 is a novel and potential PARP inhibitor with potential anticancer activity. PJ34 has a high affinity for PARP-1 (IC(50) = 20 nM) .
BYK 204165 is a potent and selective poly(ADP-ribose) polymerase (PARP)-1 inhibitor (pIC50 = 5.38 and 7.35 for PARP-2 and PARP-1, respectively). BYK 204165 is 1...
RLLFT-NH is a reversed amino acid sequence control peptide for TFLLR-NH2. TFLLR-NH2 is a peptide derived from the protease-activated receptor-1 (PAR1) that acts...
3-Aminobenzamide is a competitive PARP inhibitor with Ki of 1.8 μM.
4-HQN is a poly(ADP-ribose) polymerase (PARP) inhibitor (IC50 = 9.5 μM). 4-HQN exhibits antianti-ischemic activity and reduces ROS production, subsequent mitoch...
AY-NH is a selective proteinase-activated receptor 4 (PAR4) receptor agonist peptide. It stimulates aggregation of rat and human platelets in vitro. It reduces ...
TFLLR-NH2, derived from the protease-activated receptor-1 (PAR1), is a selective PAR1 agonist with an EC50 of 1.9 μM.
1,5-Isoquinolinediol is a PARP1 inhibitor (IC50 value 0.39 - 1.00 μM) and neuroprotective agent leading to an increase up to 8-fold in the absolute frequency of...
MK-4827 HCl is a selective inhibitor of PARP1/PARP2 with IC50 of 3.8 nM/2.1 nM. It has a great activity in cancer cells with mutant BRCA-1 and BRCA-2, >330-fold...
G007-LK is a potent, "rule of 5" compliant and a metabolically stable TNKS1/2 inhibitor. G007-LK displayed high selectivity toward tankyrases 1 and 2 with bioch...
UPF 1069 is a selective PARP2 inhibitor with IC50 of 0.3 μM. It is ~27-fold selective against PARP1.PARP activity is evaluated by utilizing commercially availab...
MK-4827 (R-enantiomer) is the R form of MK-4827, which is a PARP inhibitor developed for the treatment of ovarian cancer.
AZD2461 is a novel and potent PARP inhibitor with lower affinity to P-glycoprotein. AZD2641 is currently in Phase I clinical study. The study is being conducted...
KU 0058948 hydrochloride is a potent poly ADP-ribose polymeras (PARP) inhibitor (IC50: 3.4 nM for PARP1). In vitro, KU-0058948 activates transfected extracellul...
E7449 is an orally bioavailable, potent, small molecule inhibitor of PARP1 and PARP2, which enhances the efficacy of radiotherapy and chemotherapy and has poten...